Mode
Text Size
Log in / Sign up
N/A N=73 Randomized Treatment

Exoskeletal-assisted Walking to Improve Mobility, Bowel Function and Cardio-Metabolic Profiles in Persons With SCI

Spinal Cord Injury · Paraplegia · Tetraplegia

Enrolled (actual)
73
Serious AEs
8.0%
Results posted
May 2025
Primary outcome: Primary: 10meter Walk Test — 46; 48 Participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Exoskeletal-assisted walking (ReWalk, Ekso) (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
James J. Peters Veterans Affairs Medical Center
Primary completion
Sep 2019

Outcome Measures

OutcomeResultp-value
PRIMARY
10meter Walk Test
46; 48
PRIMARY
6min Walk Test
46; 48
PRIMARY
Timed-Up-and-Go Test (TUG)
50; 48
PRIMARY
Number of Participants With Advanced Walking Skills
42; 44; 40; 44; 46; 48
SECONDARY
Bowel Function
49.7; 50.8; 48.4; 49.3
SECONDARY
Body Fat Mass
23.6; 22.4; 22.1; 22.8

Summary

The primary objective of this study is to achieve successful walking skills using exoskeletal walking devices over the course of 36 sessions in 3 months at specific velocities and distances in people with chronic SCI who are wheelchair dependent for community mobility. The secondary objectives are to determine if this amount of exoskeletal walking is effective in improving bowel function and body composition in the same patient population. The exploratory objectives are to address additional questions concerning the retention or non-retention of the positive changes, the effects of the increased physical activity from this intervention on vagal tone, orthostatic tolerance, lipid profile, total testosterone, estradiol levels, and quality of life (QOL). A Phase III randomized clinical trial (RCT) will be performed using a crossover design and employing an exoskeletal-assisted walking intervention. The experimental arm will be compared to a usual activities (UA) arm, as the control, in 64 persons with chronic SCI (>6 month post injury) who are wheelchair-dependent for outdoor mobility in the community. The WALK arm will consist of supervised exoskeletal-assisted walking training, three sessions per week (4-6 h/week) for 36 sessions for their second 12-week period. The UA arm will consist of identification of usual activities for each participant, encouragement to continue with these activities and attention by study team members throughout the 12-week UA arm. These activities will be recorded in a weekly log. The investigators hypotheses are that 1) this exoskeletal intervention will be successful in training ambulatory skills in this patient population, 2) the exoskeletal intervention will be better than a control group in improving body composition, bowel function, metabolic parameters and quality of life in the same population.

Eligibility Criteria

Inclusion Criteria

  • Males and females, between 18-70 years old
  • Traumatic or non-traumatic paraplegia >6 months in duration
  • SCI motor deficit at any level
  • Unable to ambulate faster than 0.17 m/s on level ground with or without an assistive device and are wheelchair-dependent for community mobility
  • Height 160 to 190 cm (63-75 in or 5'3" to 6'3" ft)
  • Weight 140, DBP>90 mmHg)
  • Symptomatic orthostatic hypotension with standing that does not resolve after attempts at upright posture that were made over several days, and standing by the participant is deemed to pose a health risk, as determined by a physician, because of symptomatic orthostatic hypotension
  • Systemic or peripheral infection
  • Atherosclerosis, congestive heart failure, or history of myocardial infarction;
  • Trunk and/or lower extremity pressure ulcers
  • Severe spasticity (defined by an Ashworth score of >4.0 or clinical impression of the study physician or physical therapist)
  • Significant contractures defined as flexion contracture limited to 25º at the hip and knee
  • Diagnosis of heterotropic ossification of the lower extremities which affect range of motion or proper measurement of BMD measurements
  • Psychopathology documentation in the medical record or history of that may conflict with study objectives
  • Pregnancy and/or lactating females
  • Brain injury with score on mini-mental status examination less than 26
  • Diagnosis of coronary artery disease that precludes moderate to intense exercise
  • Deep vein thromboses in lower extremities of less than 6 months duration
  • Other illness, that the study physician considers in his/her clinical judgment to be exclusionary.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02314221). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search